Serengen GmbH

Serengen's novel CeDEC technology brings modern screening compound design to the world of DNA-encoded libraries (DELs). For the first time, a broad range of organic synthesis methods can be applied in the presence of DNA. Our unique encoding strategy allows for the synthesis of diverse chemical scaffolds with drug-like structural features. Adding drug discovery-proven substituents guarantees that these favourable attributes are kept and the chemical space is sampled in a meaningful manner. Quality control and purification steps during production ensure high fidelity of our DELs. Drug-like hits that can be directly fed into the lead generation process are your benefit. The attrition associated with transforming current DEL hits into tractable lead structures is eliminated. Serengen's Technology USPs: - New medicinal chemistry-desired chemical space for DELs is unlocked. - Modern screening compound design principles make their way into the DEL world. - Lead generation is accelerated by delivering tractable druglike hits. What is new about Serengen's Technology? - Chemically stabilized DNA is compatible with a wide range modern synthesis methods. - Solid phase synthesis process allows for the use of organic solvents under dry conditions. - Broad range of synthesis methods becomes compatible with DEL synthesis. - The synthesis of diverse chemical scaffolds with drug-like structural features is made possible. - Modern screening compound design is brought to the world of DNA-encoded libraries. - Drug-like DELs deliver drug-like hits that can be directly fit into the drug discovery process. - The attition associated with transforming current DEL hits into tractable lead structures is eliminated. - The lead generation process is accelerated. - New medicinal chemistry-desired chemical space for DELs is unlocked.